Obstructive Sleep Apnea
Respiratory·MeSH: Sleep Apnea, Obstructive
Prevalence
15000.0 / 100K
Incidence
1000.0 / 100K/yr
7 drugs in development·7 companies·17 clinical trials
Drug Pipeline by Phase
Approved(4)
Phase 2(1)
Phase 1(1)
| Drug | Company |
|---|---|
| maridebart cafraglutide | AMGEN INC (AMGN) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| ihl-42x | Incannex Healthcare Inc. (IXHL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Obstructive Sleep Apnea?
BioSniper tracks 7 drugs in development for Obstructive Sleep Apnea across 7 companies.
How many clinical trials target Obstructive Sleep Apnea?
There are 17 clinical trials targeting Obstructive Sleep Apnea tracked by BioSniper.
What is the prevalence of Obstructive Sleep Apnea?
The estimated prevalence of Obstructive Sleep Apnea is approximately 15000.0 per 100,000 population.
Deep-dive into Obstructive Sleep Apnea
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis